treatment options for the young cll patient with deletion 17p: do they need a different approach?
Published 5 years ago • 1.2K plays • Length 19:42Download video MP4
Download video MP3
Similar videos
-
21:05
cll: optimal approaches for patients with deletion 17p
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
27:18
novel treatment options in cll
-
15:23
debate: optimal approach for the management of cll patients with del(17p) - ibrutinib
-
24:17
combination of novel agents in cll: is this the final answer?
-
3:30
treatment options for young, newly diagnosed & low-risk patients with cll
-
20:40
cll: treatment for btki progressors
-
27:08
"my 28-year journey as a multiple myeloma cancer patient" - yelak biru | resilience beyond survival
-
23:32
what's next in cll?
-
20:43
venetoclax resistance: mechanisms and treatment options
-
6:28
ibrutinib for cll with deletion 17p
-
27:28
risk assessment in cll treatment
-
5:12
case 2: choosing treatment for cll with del(17p)
-
12:53
selecting first-line treatment for chronic lymphocytic leukemia (cll)
-
24:09
update on venetoclax for cll
-
22:08
role of chemotherapy in cll management
-
1:19
treatment recommendations for patients with cll with del(17p) and tp53 aberrations
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
1:47
age impacts treatment options for patients with cll